Jeffrey Lombardi

Jeffrey Lombardi

Auto-generated profile, based on publicly available information

Jeffrey Lombardi

Pharmacy Department, Centre Georges-François Leclerc, Dijon, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
JLJeffrey Lombardi
Jeffrey Lombardi
MBMathieu Boulin
Mathieu Boulin
MDMadeline Devaux
Madeline Devaux
ACAmélie CRANSAC
Amélie CRANSAC
PPPauline Pistre
Pauline Pistre
PGPauline Gueneau
Pauline Gueneau
Purpose: Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) are frequent during the first and second infusions. Due to the risks associated with severe IRRs, daratumumab is systematically administered over a period of 3.5 hours. The main objective of this study was to evaluate the safety of a 90-minute daratumumab infusion from the third infusion. Patients and methods: All patients who had received two or more doses of daratumumab in monotherapy or in combination with standard infusion rates were included. We excluded patients enrolled in clinical trials. For the rapid infusion protocol, 20% of the dose was administered over 30 minutes and the remaining 80% over 60 minutes. Results: From April 1 to May 31, 2019, 25 patients received 53 90-minute infusions of daratumumab. Premedication included corticosteroids, antipyretics, antihistamines, and if necessary a leukotriene receptor antagonist. No grade 3 or grade 4 IRRs were observed. Conclusion: From the third infusion, we found that a rapid administration of daratumumab (90 vs 210 minutes) was well tolerated and safe. It would be interesting to test this regimen from the second infusion.

18 May 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
JLJeffrey Lombardi
Jeffrey Lombardi
PLPauline Lory
Pauline Lory
NMNils Martin
Nils Martin
DMDidier Mayeur
Didier Mayeur
SCSandrine Combret
Sandrine Combret
ASAntonin Schmitt
Antonin Schmitt
Introduction: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1). Case report: We report the first case of T-DM1-associated pleural and pericardial effusions three weeks after the second course of T-DM1 in a patient with breast cancer. Drug-induced pleural and pericardial effusions was implicated in the absence of other etiologies. The Naranjo Scale indicated a probable drug-induced adverse reaction. Management & outcome: The patient fully recovered after thoracentesis and discontinuation of T-DM1. The patient has reported no side effect after the sixth course of trastuzumab. Discussion: To our knowledge, this is the first case in the literature of bilateral pleural and pericardial effusions in a patient treated with T-DM1. The successful initiation of treatment with trastuzumab following withdrawal of T-DM1 suggests that emtansine played a role in the development of bilateral pleural and pericardial effusions. We hypothesize that the patient’s condition was a result of a local inflammatory reaction to emtansine by direct toxicity.

1 March 2018 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
JLJ. Lombardi
J. Lombardi
DSD.S. Semama
D.S. Semama

1 December 2020 in Le Pharmacien Hospitalier et Clinicien
Verified
Journal Article
Closed access
JLJeffrey Lombardi
Jeffrey Lombardi
CPChristelle Prudent
Christelle Prudent
JCJulia Cregut-Corbaton
Julia Cregut-Corbaton